omega-n-methylarginine has been researched along with pioglitazone in 3 studies
| Studies (omega-n-methylarginine) | Trials (omega-n-methylarginine) | Recent Studies (post-2010) (omega-n-methylarginine) | Studies (pioglitazone) | Trials (pioglitazone) | Recent Studies (post-2010) (pioglitazone) |
|---|---|---|---|---|---|
| 4,411 | 344 | 336 | 4,338 | 824 | 2,277 |
| Protein | Taxonomy | omega-n-methylarginine (IC50) | pioglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1 | |
| Bile salt export pump | Rattus norvegicus (Norway rat) | 2 | |
| Peroxisome proliferator-activated receptor gamma | Rattus norvegicus (Norway rat) | 0.7 | |
| Bile salt export pump | Homo sapiens (human) | 0.337 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.114 | |
| Steryl-sulfatase | Homo sapiens (human) | 0.8 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 1.15 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.298 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 3.0379 | |
| Peroxisome proliferator-activated receptor gamma | Mus musculus (house mouse) | 0.7 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 4.8 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 8.65 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aizawa, Y; Hasebe, N; Kawabe , J; Kikuchi, K; Takehara, N | 1 |
| Han, YQ; Koshinaka, K; Ohsawa, I; Oshida, Y; Sato, Y | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Yoshida, K | 1 |
3 other study(ies) available for omega-n-methylarginine and pioglitazone
| Article | Year |
|---|---|
Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia.
Topics: Animals; Apoptosis; Carotid Arteries; Carotid Artery Injuries; Catheterization; Cell Division; Cell Survival; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Hyperplasia; In Situ Nick-End Labeling; Interferon-gamma; Interleukin-1; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; omega-N-Methylarginine; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Tunica Intima | 2001 |
The effect of nitric oxide synthase inhibitor on improved insulin action by pioglitazone in high-fructose-fed rats.
Topics: Animals; Body Weight; Dietary Carbohydrates; Eating; Enzyme Inhibitors; Fructose; Glucose; Glucose Clamp Technique; Hypoglycemic Agents; Insulin; Male; Muscle, Skeletal; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; omega-N-Methylarginine; Pioglitazone; Rats; Rats, Wistar; Thiazolidinediones | 2004 |
Effects of pioglitazone on nitric oxide bioavailability measured using a catheter-type nitric oxide sensor in angiotensin II-infusion rabbit.
Topics: Acetylcholine; Angiotensin II; Animals; Biopterins; Biosensing Techniques; Blood Pressure; Calibration; Catheterization; Enzyme Inhibitors; Heart Rate; Hypoglycemic Agents; Immunohistochemistry; Male; Nitric Oxide; omega-N-Methylarginine; Pioglitazone; PPAR gamma; Rabbits; Thiazolidinediones; Tyrosine; Vasoconstrictor Agents; Vasodilator Agents | 2008 |